Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Pro Medicus Limited ( (AU:PME) ) has shared an announcement.
Pro Medicus Limited has notified the market that 3,134 performance rights (PMEAL) have lapsed after the conditions attached to these rights were not met or became incapable of being satisfied, effective 31 October 2025. The cessation of these securities represents a minor adjustment to the company’s issued capital structure and reflects the operation of its performance-based incentive arrangements, with limited immediate impact on ordinary shareholders but some implications for the allocation of executive or employee equity incentives.
The most recent analyst rating on (AU:PME) stock is a Buy with a A$350.00 price target. To see the full list of analyst forecasts on Pro Medicus Limited stock, see the AU:PME Stock Forecast page.
More about Pro Medicus Limited
Pro Medicus Limited is an Australian-listed healthcare technology company (ASX: PME) that develops and supplies medical imaging IT solutions, including radiology information systems and picture archiving and communication systems, to hospitals, imaging centres and healthcare providers in domestic and international markets.
Average Trading Volume: 171,510
Technical Sentiment Signal: Hold
Current Market Cap: A$21.96B
For an in-depth examination of PME stock, go to TipRanks’ Overview page.